<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Donepezil: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Donepezil: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Donepezil: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12393" href="/d/html/12393.html" rel="external">see "Donepezil: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F162576"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Adlarity;</li>
<li>Aricept</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866653"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>ACH-Donepezil;</li>
<li>ACT Donepezil ODT [DSC];</li>
<li>AG-Donepezil;</li>
<li>APO-Donepezil;</li>
<li>Aricept;</li>
<li>Aricept RDT [DSC];</li>
<li>Auro-Donepezil;</li>
<li>BIO-Donepezil;</li>
<li>JAMP-Donepezil;</li>
<li>M-Donepezil;</li>
<li>Mar-Donepezil;</li>
<li>MINT-Donepezil;</li>
<li>NAT-Donepezil;</li>
<li>NRA-Donepezil;</li>
<li>PMS-Donepezil;</li>
<li>PRIVA-Donepezil [DSC];</li>
<li>SANDOZ Donepezil;</li>
<li>SANDOZ Donepezil ODT [DSC];</li>
<li>Septa-Donepezil [DSC];</li>
<li>TARO-Donepezil;</li>
<li>TEVA-Donepezil</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F162609"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Acetylcholinesterase Inhibitor (Central)</li></ul></div>
<div class="block doa drugH1Div" id="F162581"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a3041b3d-3f11-47c1-815e-01b475c1f691">Alzheimer disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Alzheimer disease:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b></p>
<p style="text-indent:-2em;margin-left:6em;">Mild to moderate: Initial: 5 mg once daily; may increase to 10 mg once daily after 4 to 6 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29923184','lexi-content-ref-10325453','lexi-content-ref-11044775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29923184','lexi-content-ref-10325453','lexi-content-ref-11044775'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Moderate to severe: Initial: 5 mg once daily; may increase to 10 mg once daily after 4 to 6 weeks; may increase further to 23 mg once daily if stable on 10 mg daily for ≥3 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29923184','lexi-content-ref-20678673','lexi-content-ref-26967222']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29923184','lexi-content-ref-20678673','lexi-content-ref-26967222'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note:</b> Doses of 23 mg/day may be associated with a limited increase in efficacy compared to 10 mg/day and with increased adverse effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29923184','lexi-content-ref-20678673']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29923184','lexi-content-ref-20678673'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Transdermal:</b> Initial: 5 mg per 24-hour patch applied once weekly; may increase to 10 mg per 24-hour patch applied once weekly after 4 to 6 weeks (maximum: 10 mg per 24 hours).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Missed dose</i>: If a patch falls off or a dose is missed, apply a new patch immediately and then replace this patch 7 days later to start a new one-week cycle.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6f31d5dd-8c2e-4f4c-aeb7-2f04acca998c">Dementia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Dementia (ie, Parkinson disease dementia, dementia with Lewy bodies, comorbid vascular dementia) (off-label use): Oral:</b> Initial: 5 mg once daily; may increase to 10 mg once daily after 4 to 6 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18340692','lexi-content-ref-26918649','lexi-content-ref-NICE.2018','lexi-content-ref-24828899']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18340692','lexi-content-ref-26918649','lexi-content-ref-NICE.2018','lexi-content-ref-24828899'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Transitioning from oral to transdermal: </b>Patients being treated with a total oral daily dose of 5 mg may be switched to 5 mg per 24-hour patch applied once weekly. Patients being treated with a total oral daily dose of 5 mg for at least 4 to 6 weeks may be increased to a 10 mg per 24-hour patch applied once weekly. Patients being treated with a total oral daily dose of 10 mg may be switched to the 10 mg per 24-hour patch applied once weekly.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>
<i>Discontinuation of therapy: </i></b>Discontinuation of therapy may result in worsening of cognitive function (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22397651']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22397651'])">Ref</a></span>). Avoid abrupt discontinuation except in the case of severe adverse drug reaction to minimize withdrawal symptoms (eg, altered mental status, hallucinations, delusions, insomnia, increased anxiety and agitation). In general, cholinesterase inhibitors should be tapered using a 50% dose reduction or stepwise reduction via available dose formulations every 4 weeks to the lowest dose prior to discontinuation. Consider re-initiation if clear worsening of the condition occurs after withdrawal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26515660','lexi-content-ref-30771226']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26515660','lexi-content-ref-30771226'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990691"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b>
<b>Oral, transdermal: </b>Mild to severe impairment: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15496219','lexi-content-ref-9839768','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15496219','lexi-content-ref-9839768','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b>
<b>Oral, transdermal: </b>Unlikely to be dialyzed (highly protein bound): No supplemental dose or dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12053074','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12053074','lexi-content-ref-Expert.DOR'])">Ref</a></span>). One small case series in hemodialysis patients reported efficacy and tolerability using an initial oral dose of 2.5 mg/day titrated to 5 mg/day after 1 month (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31616673']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31616673'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b>
<b>Oral, transdermal: </b>Unlikely to be dialyzed (highly protein bound): No supplemental dose or dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988005"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling. </p></div>
<div class="block doe drugH1Div" id="F162582"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing. <b>Note:</b> The Canadian labeling recommends a maximum dose of 5 mg once daily in elderly women (≥85 years of age) of low body weight.</p></div>
<div class="block arsc drugH1Div" id="F54425013"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Cardiac effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Acetylcholinesterase inhibitors, including donepezil, have been associated with cardiac effects, such as conduction abnormalities (eg, <b>atrioventricular block</b>, arrhythmias [including <b>prolonged QT interval on ECG </b>and <b>torsades de pointes</b>], <b>bradycardia</b>) and <b>hypertension</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25484499','lexi-content-ref-17855324','lexi-content-ref-16858101','lexi-content-ref-19602789']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25484499','lexi-content-ref-17855324','lexi-content-ref-16858101','lexi-content-ref-19602789'])">Ref</a></span>). <b>Syncope </b>has also been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29851022','lexi-content-ref-21648211']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29851022','lexi-content-ref-21648211'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Related to the mechanism of action; increased cholinergic activity results in vagotonic effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29851022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29851022'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Delayed; reported months to years after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29851022','lexi-content-ref-17855324','lexi-content-ref-21648211','lexi-content-ref-19602789']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29851022','lexi-content-ref-17855324','lexi-content-ref-21648211','lexi-content-ref-19602789'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Older adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29851022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29851022'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of cardiovascular disease (eg, ischemic heart disease, heart failure) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hernandez.2016']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hernandez.2016'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of cardiac conduction abnormalities or sick sinus syndrome (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hernandez.2016','lexi-content-ref-31997970']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hernandez.2016','lexi-content-ref-31997970'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of stroke or transient ischemic attack, diabetes, or syncope (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hernandez.2016']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hernandez.2016'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent antihypertensives (especially beta-blockers), antiarrhythmics, antidepressants, and antipsychotics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29851022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29851022'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">GI effects and weight loss</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Dose-related GI effects are the most common adverse reactions associated with donepezil. Symptoms may include <b>nausea</b>, <b>vomiting</b>, and <b>diarrhea</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18686744']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18686744'])">Ref</a></span>). A systematic review of studies reported less GI effects with donepezil compared to rivastigmine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19893314']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19893314'])">Ref</a></span>). In another study, donepezil had the lowest rates of GI effects except for diarrhea compared to both galantamine and rivastigmine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18686744']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18686744'])">Ref</a></span>). <b>Weight loss</b> and/or <b>anorexia</b> may also occur. GI effects are typically transient and self-limiting with resolution within 1 to 3 weeks of initiation.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; related to mechanism of action. Increased cholinergic activity increases smooth muscle contraction, peristalsis, and sphincter relaxation in the GI tract, leading to GI effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26234945','lexi-content-ref-27261502']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26234945','lexi-content-ref-27261502'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; weight loss/anorexia may occur from the beginning of treatment to any time within the first year of therapy. More research is needed in this area, especially beyond 1 year (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16553494','lexi-content-ref-26234945','lexi-content-ref-27261502']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16553494','lexi-content-ref-26234945','lexi-content-ref-27261502'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (≥10 mg/day)</p>
<p style="text-indent:-2em;margin-left:6em;">• Dose initiation or titration</p>
<p style="text-indent:-2em;margin-left:6em;">• Patients weighing &lt;55 kg</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F162548"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling for oral formulations unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (dose-related; 5% to 15%)<span class="lexi-table-link-container"> (<a aria-label="Diarrhea table link" class="lexi-table-link" data-table-id="lexi-content-diarrhea" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-diarrhea')">table 1</a>)</span><span class="table-link" style="display:none;">Diarrhea</span>, nausea (dose-related; 3% to 19%)<span class="lexi-table-link-container"> (<a aria-label="Nausea table link" class="lexi-table-link" data-table-id="lexi-content-nausea" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-nausea')">table 2</a>)</span><span class="table-link" style="display:none;">Nausea</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Diarrhea" frame="border" id="lexi-content-diarrhea" rules="all">
<caption style="text-align:center;">
<b>Donepezil: Adverse Reaction: Diarrhea</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Donepezil)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Donepezil)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">15%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mild to moderate Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">315</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">315</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">One-week titration</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5 mg/day or 10 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mild to moderate Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">747</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">355</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mild to moderate Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">311</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">315</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">No titration</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">23 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Moderate to severe Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">963</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Moderate to severe Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">471</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5 mg/day or 10 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Severe Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">501</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">392</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Nausea" frame="border" id="lexi-content-nausea" rules="all">
<caption style="text-align:center;">
<b>Donepezil: Adverse Reaction: Nausea</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Donepezil)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Donepezil)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">19%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mild to moderate Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">315</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">315</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">One-week titration</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5 mg/day or 10 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mild to moderate Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">747</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">355</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mild to moderate Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">311</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">315</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">No titration</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">23 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Moderate to severe Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">963</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Moderate to severe Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">471</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5 mg/day or 10 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Severe Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">501</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">392</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Local: Application-site reaction (transdermal: including application-site dermatitis, application-site edema [&lt;1%], application-site erythema [65%], application-site pain, application-site pruritus, papule of skin [16%: application-site])</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Insomnia (2% to 14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Accidental injury (7% to 13%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain (2%), hypertension (3%)<span class="lexi-table-link-container"> (<a aria-label="Hypertension table link" class="lexi-table-link" data-table-id="lexi-content-hypertension" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-hypertension')">table 3</a>)</span><span class="table-link" style="display:none;">Hypertension</span>, syncope (2%)<span class="lexi-table-link-container"> (<a aria-label="Syncope table link" class="lexi-table-link" data-table-id="lexi-content-syncope" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-syncope')">table 4</a>)</span><span class="table-link" style="display:none;">Syncope</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Hypertension" frame="border" id="lexi-content-hypertension" rules="all">
<caption style="text-align:center;">
<b>Donepezil: Adverse Reaction: Hypertension</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Donepezil)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Donepezil)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5 mg/day or 10 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Severe Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">501</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">392</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Syncope" frame="border" id="lexi-content-syncope" rules="all">
<caption style="text-align:center;">
<b>Donepezil: Adverse Reaction: Syncope</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Donepezil)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Donepezil)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5 mg/day or 10 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mild to moderate Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">747</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">355</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5 mg/day or 10 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Severe Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">501</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">392</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Ecchymoses (4% to 5%), eczema (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperlipidemia (2%), weight loss (dose-related; 3% to 5%)<span class="lexi-table-link-container"> (<a aria-label="Weight Loss table link" class="lexi-table-link" data-table-id="lexi-content-weight-loss" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-weight-loss')">table 5</a>)</span><span class="table-link" style="display:none;">Weight Loss</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Weight Loss" frame="border" id="lexi-content-weight-loss" rules="all">
<caption style="text-align:center;">
<b>Donepezil: Adverse Reaction: Weight Loss</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Donepezil)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Donepezil)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5 mg/day or 10 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mild to moderate Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">747</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">355</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">23 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Moderate to severe Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">963</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Moderate to severe Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">471</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia (dose-related; 2% to 8%)<span class="lexi-table-link-container"> (<a aria-label="Anorexia table link" class="lexi-table-link" data-table-id="lexi-content-anorexia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-anorexia')">table 6</a>)</span><span class="table-link" style="display:none;">Anorexia</span>, gastrointestinal hemorrhage (1%), vomiting (dose-related; 3% to 9%)<span class="lexi-table-link-container"> (<a aria-label="Vomiting table link" class="lexi-table-link" data-table-id="lexi-content-vomiting" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-vomiting')">table 7</a>)</span><span class="table-link" style="display:none;">Vomiting</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Anorexia" frame="border" id="lexi-content-anorexia" rules="all">
<caption style="text-align:center;">
<b>Donepezil: Adverse Reaction: Anorexia</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Donepezil)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Donepezil)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mild to moderate Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">315</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">315</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">One-week titration</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5 mg/day or 10 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mild to moderate Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">747</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">355</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mild to moderate Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">311</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">315</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">No titration</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">23 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Moderate to severe Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">963</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Moderate to severe Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">471</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5 mg/day or 10 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Severe Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">501</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">392</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Vomiting" frame="border" id="lexi-content-vomiting" rules="all">
<caption style="text-align:center;">
<b>Donepezil: Adverse Reaction: Vomiting</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Donepezil)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Donepezil)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mild to moderate Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">315</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">315</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">One-week titration</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5 mg/day or 10 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mild to moderate Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">747</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">355</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mild to moderate Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">311</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">315</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">No titration</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">23 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Moderate to severe Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">963</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Moderate to severe Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">471</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5 mg/day or 10 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Severe Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">501</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">392</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary frequency (2%), urinary incontinence (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Bruise (2%), hemorrhage (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal dreams (3%), asthenia (1% to 2%), confusion (2%), depression (2% to 3%), dizziness (2% to 8%), drowsiness (1% to 2%), emotional lability (2%), fatigue (1% to 8%), hallucination (3%), headache (3% to 10%), hostility (3%), nervousness (3%), pain (3% to 9%), personality disorder (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthritis (2%), back pain (3%), increased creatine phosphokinase in blood specimen (3%), muscle cramps (6% to 8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (2%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Gastrointestinal: Peptic ulcer</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing (any formulation):</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Atrioventricular block (Hundae 2014; Suleyman 2006), bradycardia (Suleyman 2006), prolonged QT interval on ECG (Leitch 2007; Tanaka 2009), torsades de pointes (Tanaka 2009)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (Lim 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyponatremia (Shareef 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Cholecystitis, pancreatitis (Niinomi 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Hemolytic anemia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatitis (Dierckx 2008; Verrico 2000)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Aggressive behavior, agitation (Leung 2014), neuroleptic malignant syndrome (Matsumoto 2004; Warwick 2008), seizure (Babic 1999; Kumlien 2010)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Rhabdomyolysis (Fleet 2019; Sahin 2014)</p></div>
<div class="block coi drugH1Div" id="F162560"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;margin-left:0em;">Hypersensitivity to donepezil, piperidine derivatives, or any component of the formulation; patients with a history of contact dermatitis with the use of transdermal donepezil (transdermal).</p></div>
<div class="block war drugH1Div" id="F162545"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Rhabdomyolysis: Rare cases of rhabdomyolysis (including acute renal failure) have been reported after a few months of therapy (Sahin 2014) or in the days following therapy initiation and dose increase (Aricept Canadian product monograph 2014). Use with caution in patients with risk factors for rhabdomyolysis (eg, concomitant medications associated with rhabdomyolysis, history of muscular disorders, uncontrolled hypothyroidism, renal/hepatic impairment). Discontinuation of therapy may be necessary for marked elevation of CPK levels and/or symptoms (eg, muscle pain, tenderness or weakness, malaise, fever, dark urine) suggesting rhabdomyolysis.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Peptic ulcer disease: Use with caution in patients at risk of ulcer disease (eg, previous history or NSAID use); cholinesterase inhibitors may increase gastric acid secretion. Monitor for symptoms of bleeding.</p>
<p style="text-indent:-2em;margin-left:4em;">• Respiratory disease: Use with caution in patients with chronic obstructive pulmonary disease and/or asthma.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizure disorder: Use with caution in patients with a history of seizure disorder; cholinomimetics may potentially cause generalized seizures, although seizure activity may also result from Alzheimer disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Urinary tract obstruction: Use with caution in patients with bladder outlet obstruction; cholinomimetics may cause or worsen outflow obstructions.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>
<b>
<i>Dosage form specific issues</i></b>:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Aspartame: Some products may contain aspartame, which is metabolized to phenylalanine and must be avoided (or used with caution) in patients with phenylketonuria.</p>
<p style="text-indent:-2em;margin-left:4em;">• Transdermal: Application-site reactions have been reported, which may lead to contact dermatitis; discontinue therapy if an intense local reaction occurs (eg, increasing erythema, edema, papules, vesicles) and if symptoms do not improve after 48 hours of patch removal.</p></div>
<div class="block foc drugH1Div" id="F162555"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Patch Weekly, Transdermal, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Adlarity: 5 mg/day (1 ea, 4 ea); 10 mg/day (1 ea, 4 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Aricept: 5 mg, 10 mg, 23 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg, 10 mg, 23 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Disintegrating, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg, 10 mg</p></div>
<div class="block geq drugH1Div" id="F162541"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F162563"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Patch weekly</b> (Adlarity Transdermal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg/day (per each): $135.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/day (per each): $135.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, orally-disintegrating</b> (Donepezil HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $7.79</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $7.79</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Aricept Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $20.24</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $20.24</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">23 mg (per each): $18.10</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Donepezil HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $0.18 - $8.67</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $0.18 - $8.67</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">23 mg (per each): $10.41 - $11.36</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866654"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Aricept: 5 mg, 10 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg, 10 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Disintegrating, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Aricept RDT: 5 mg [DSC], 10 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg [DSC], 10 mg [DSC]</p></div>
<div class="block adm drugH1Div" id="F759356"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Oral: Administer at bedtime without regard to food.</p>
<p style="text-indent:-2em;margin-left:4em;">Aricept 23 mg tablet: Swallow whole with water; do <b>NOT</b> crush or chew due to an increased rate of absorption. The 23 mg strength is provided in a unique film-coated formulation different from the 5 mg or 10 mg tablet strengths, which results in an altered pharmacokinetic profile.</p>
<p style="text-indent:-2em;margin-left:4em;">Aricept ODT: Allow tablet to dissolve completely on tongue and follow with water.</p>
<p style="text-indent:-2em;margin-left:2em;">Transdermal: Allow patch pouch to reach room temperature prior to removing from packaging for application; do not use external heat sources to warm. Use within 24 hours of removing from the refrigerator; do not apply a cold patch. Patches should be applied weekly to a clean, hairless area of the back avoiding the spine (preferred), upper buttocks, or upper outer thigh; avoid a location that may be rubbed by tight clothing. Press firmly for 30 seconds to ensure proper adherence. Do not apply to red, irritated, or cut skin or an area where medication, cream, lotion, or powder has been applied. Do not shave the site. Rotate patch sites weekly; do not use the same site for at least 14 days. May bathe while wearing patch. Avoid long exposure to external heat sources (eg, excessive sunlight, heating pads, saunas, solariums). Dispose of any used patches by folding adhesive ends together and discard properly in trash away from children and pets; do not flush down the toilet.</p></div>
<div class="block use drugH1Div" id="F162557"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Alzheimer disease:</b> Treatment of mild, moderate, or severe dementia of the Alzheimer type.</p></div>
<div class="block off-label drugH1Div" id="F25725331"><span class="drugH1">Use: Off-Label: Adult</span><p>Dementia (ie, Parkinson disease dementia, dementia with Lewy bodies, comorbid vascular dementia)</p></div>
<div class="block mst drugH1Div" id="F162616"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Aricept may be confused with AcipHex, Ascriptin, and Azilect</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F162602"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2D6 (minor), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F162550"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Amifampridine: Acetylcholinesterase Inhibitors may enhance the therapeutic effect of Amifampridine. Amifampridine side effects may also be increased. Amifampridine may enhance the therapeutic effect of Acetylcholinesterase Inhibitors. Acetylcholinesterase inhibitor side effects may also be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticholinergic Agents: Acetylcholinesterase Inhibitors may diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents: Donepezil may enhance the neurotoxic (central) effect of Antipsychotic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benoxinate: Acetylcholinesterase Inhibitors may enhance the therapeutic effect of Benoxinate. Specifically, the effects of benoxinate may be prolonged. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers: Acetylcholinesterase Inhibitors may enhance the bradycardic effect of Beta-Blockers. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bradycardia-Causing Agents: May enhance the bradycardic effect of other Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ceritinib: Bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib.  Management: If this combination cannot be avoided, monitor patients for evidence of symptomatic bradycardia, and closely monitor blood pressure and heart rate during therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorprothixene: Acetylcholinesterase Inhibitors may enhance the adverse/toxic effect of Chlorprothixene. Acetylcholinesterase Inhibitors may enhance the therapeutic effect of Chlorprothixene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholinergic Agonists: Acetylcholinesterase Inhibitors may enhance the adverse/toxic effect of Cholinergic Agonists. Specifically, cholinergic effects may be enhanced or increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May enhance the adverse/toxic effect of Acetylcholinesterase Inhibitors. Increased muscular weakness may occur.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyridamole: May diminish the therapeutic effect of Acetylcholinesterase Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Bradycardia-Causing Agents may enhance the arrhythmogenic effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fingolimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Fingolimod.  Management: Consult with the prescriber of any bradycardia-causing agent to see if the agent could be switched to an agent that does not cause bradycardia prior to initiating fingolimod. If combined, perform continuous ECG monitoring after the first fingolimod dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of Haloperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivabradine: Bradycardia-Causing Agents may enhance the bradycardic effect of Ivabradine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lacosamide: Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midodrine: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular-Blocking Agents (Nondepolarizing): Acetylcholinesterase Inhibitors may diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ponesimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Ponesimod.  Management: Avoid coadministration of ponesimod with drugs that may cause bradycardia when possible. If combined, monitor heart rate closely and consider obtaining a cardiology consult. Do not initiate ponesimod in patients on beta-blockers if HR is less than 55 bpm.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Highest Risk): QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Siponimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Siponimod.  Management: Avoid coadministration of siponimod with drugs that may cause bradycardia. If combined, consider obtaining a cardiology consult regarding patient monitoring.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Succinylcholine: Acetylcholinesterase Inhibitors may enhance the neuromuscular-blocking effect of Succinylcholine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F162564"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events have been observed in some animal reproduction studies.</p></div>
<div class="block brc drugH1Div" id="F20306041"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if donepezil is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F162553"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Mental status, weight, symptoms of GI intolerance, symptoms of active or occult GI bleeding.</p></div>
<div class="block pha drugH1Div" id="F162544"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Alzheimer's disease is characterized by cholinergic deficiency in the cortex and basal forebrain, which contributes to cognitive deficits. Donepezil reversibly and noncompetitively inhibits centrally active acetylcholinesterase, the enzyme responsible for hydrolysis of acetylcholine. This appears to result in increased concentrations of acetylcholine available for synaptic transmission in the CNS.</p></div>
<div class="block phk drugH1Div" id="F162559"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral: Well absorbed; Transdermal: Delayed.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>dss</sub>: 12 to 16 L/kg.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~96%, primarily to albumin (75%) and alpha<sub>1</sub>-acid glycoprotein (21%).</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Extensive hepatic metabolism via CYP2D6 and 3A4 and glucuronidation to four major metabolites (two are active).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Oral: 70 hours; time to steady-state: 15 days; Transdermal: ~91 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: Tablet, 10 mg: 3 hours; Tablet, 23 mg: ~8 hours; Transdermal: ~7 days; <b>Note:</b> Peak plasma concentrations almost twofold higher for the 23 mg tablet compared to the 10 mg tablet.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (57%; 17% as unchanged drug); feces (15%)</p></div>
<div class="block phksp drugH1Div" id="F51153980"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Clearance decreased 20% in patients with stable alcoholic cirrhosis.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: Clearance decreases with increasing age. When compared with patients 65 years of age, 90-year-old patients have a 17% decrease in clearance, while 40-year-old patients have a 33% increase in clearance; effect may not be clinically significant.</p>
<p style="text-indent:-2em;margin-left:2em;">Body weight: For body weight from 50 to 110 kg, clearance increased from 7.77 to 14.04 L/hour, with a value of 10 L/hour for 70 kg individuals.</p>
<p style="text-indent:-2em;margin-left:2em;">CYP2D6 genotype: When compared with CYP2D6 extensive metabolizers, poor metabolizers had a 31.5% slower clearance and ultra-rapid metabolizers had a 24% faster clearance.</p>
<p style="text-indent:-2em;margin-left:2em;">Transdermal: AUC and C<sub>max</sub> were 14% to 18% lower and 21% to 24% higher, respectively, when applied to the thigh and buttocks compared to the back. Exposure was increased temporarily by up to 60% when application site was exposed to heat.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F162565"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Aricept | Donepex | Dopzil | Doxera | Tregona</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Aflimet | Alzaimax | Cebrocal | Crialix | Cristaclar | DONENOVA | Donepecilo richet | Donepecilo vannier | Donepes | Donepes Dor | Donnox | Donpex | Endoclar | Eranz | Lupracil | Oldinot | Onefin | Valpex | Valpex flash</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Aricept | Demelan | Donepezil +pharma | Donepezil accord | Donepezil actavis | Donepezil bluefish | Donepezil genericon | Donepezil HCl 1A Pharma | Donepezil hcl arcana | Donepezil hcl sandoz | Donepezil krka | Donepezil Pfizer | Donepezil ratiopharm | Donepezil Stada</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo donepezil | Arazil | Aricept | Aricept d | Aridon | Cm Donepezil | Donepezil | Donepezil an | Donepezil Drla | Donepezil Ga | Donepezil Rbx | Donepezil Sandoz | Donepezil Synthon | Noumed donepezil | Pharmacor donepezil | Stada Donepezil | Twc donepezil</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Ameloss | Elzer | Memorin</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Aricept | Donepezil Apotex | Donepezil Eg | Donepezil krka | Donepezil mylan | Donepezil Sandoz | Donepezil teva</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Alzancer | Aricept | Aripezil | Darizol | Donecept | Dopezal | Yasnal</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Aricept | Arozep | Clorhydrate de Donepezila | Cloridrato de donepezila | Danpezil | Don | Donila | Epez | Eranz | Furp donepezila | Labrea | Nepezil | Reczil | Senes | Ziledon | Zymea</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Aricept | Aricept Evess | Donepezil actavis | Donepezil Helvepharm | Donepezil Mepha | Donepezil nobel | Donepezil Sandoz | Donepezil spirig hc | Donepezil zentiva</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Aricept</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Dazolin | Donap | Dopaben | Eranz | Evimal | Evocaz cd | Fincip | Ideclar | Nepokare</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">A rui si | Aricept | Fu si ke | Nuo chong | Si bo hai</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Alzedon | Alzit | Arizil | Bradonex | Donecil | Donepecilo | Donepezilo Clorhidrato | Donepezilo de clorhidrato | Dopecilo | Eranz | Geriapexil | Glix | Lindezip | Nepecil | Pezicep</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Adonep | Alzil | Apo donepezil | Aricept | Calofra | Darezil | Donepezil +pharma | Donepezil accord | Donepezil actavis | Donepezil bluefish | Donepezil krka | Donepezil mylan | Donepezil Orion | Donepezil pmcs | Donepezil ratiopharm | Donepezil Sandoz | Donepezil teva | Donpethon | Dospelin | Kognezil | Landex | Promemore | Yasnal</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Aricept | Aricept Evess | Donepegamma | Donepezil Aaa | Donepezil Aluid | Donepezil elpen | Donepezil HCL | Donepezil HCl 1A Pharma | Donepezil hcl aurobindo | Donepezil hcl basics | Donepezil hcl betapharm | Donepezil hcl biomo | Donepezil hcl biomo pharma | Donepezil hcl CT | Donepezil hcl hexal | Donepezil hcl mylan | Donepezil hcl neuraxpharm | Donepezil hcl puren | Donepezil hcl ratiopharm | Donepezil hormosan | Donepezil hydrochloride actavis | Donepezil hydrochloride bluefish | Donepezil hydrochloride hennig | Donepezil hydrochloride heumann | Donepezil Stada | Donepezilhydrochlorid | Donepezilhydrochlorid q | Memac | Neuristor | Yasnal</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Alzil | Aricept | Donecil | Doneclar | Donepezilo Clorhidrato | Donezel | Dopezil | Dosteril | Evocaz cd | Medebral | Vio Geric | Zeuton</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Aricept | Arizil | Donecil | Doneclar | Eranz | Lirpan</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Aricept | Divare | Donepezil accord | Donepezil actavis | Donepezil Orion | Yasnal</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Alkapezil | Alzepizil | Alzimer | Aricept | Donecept | Donepezil | Donhimer | Lidemtzil | Zymadone</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Aricept | Aricept flas | Donepezilo actavis | Donepezilo almus | Donepezilo alter | Donepezilo Apotex | Donepezilo aurobindo | Donepezilo bluefish | Donepezilo cinfa | Donepezilo combix | Donepezilo Kern | Donepezilo kern pharma | Donepezilo krka | Donepezilo macleods | Donepezilo Mylan | Donepezilo Normon | Donepezilo Pensa | Donepezilo pensa pharma | Donepezilo pharmacia | Donepezilo Pharmagenus | Donepezilo qualigen | Donepezilo Ranbaxy | Donepezilo Ratiopharm | Donepezilo Sandoz | Donepezilo sanovel | Donepezilo stada | Donepezilo tarbis | Donepezilo Tecnigen | Donepezilo teva | Donepezilo Tevagen | Donepezilo ur | Donepezilo viatris | Lixben | Uxazen | Yasnal</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Aricept | Donepezil | Donepezil accord | Donepezil actavis | Donepezil bluefish | Donepezil krka | Donepezil mylan | Donepezil Orifarm | Donepezil Orion | Donepezil Sandoz | Donepezil teva | Doneratio | Dopezon | Mikzil | Yasnal | Zauton</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Aricept | Donepezil actavis | Donepezil Alter | Donepezil Arrow | Donepezil biogaran | Donepezil bluefish | Donepezil cristers | Donepezil Eg | Donepezil Evolugen | Donepezil intas | Donepezil krka | Donepezil mylan | Donepezil Pfizer | Donepezil ranbaxy | Donepezil Sandoz | Donepezil teva | Donepezil zentiva | Donepezil Zydus</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Aricept | Aricept Evess | Donepezil</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Adtreat | Aricept | Aripezil | Caricia | Cenipil | Cerebrol | Covolos | Dementis | Dezial | Donacept | Donegal | Donelet | Donepezil actavis | Donepezil genepharma | Donepezil generics | Donepezil/Generics | Donepezil/mylan | Donept | Donester | Dospelin | Dozilax | Filosept | Hania | Miltus | Nepanizil | Nepezil | Niritos | Penezil | Pezale | Peziled | Rafazil | Sulbenin | Tactrol | Venaxen | Zakalmer | Zinocept | Zopitel</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Alzedon | Alzhemept | Aricept | Aricept Evess | Donecept | Donepezil | Donepezil hcl genepharm | Vastia</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Aricept | Donepezil Pliva</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Alzepil | Aricept | Cognezil | Donecept | Donectil | Donefien | Donenorm | Donepezil accord | Donepezil bluefish | Donepezil mylan | Donepezil Orion | Donepezil Stada | Donepezil teva | Donestad | Donesyn | Palixid</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Aldomer | Aloxtra | Alzim | Aricept | Donacept | Donepezil | Dozil | Fordesia</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Aricept | Aripez | Aripil | Arizime | Donecept | Donelinn | Donepezil | Donepezil HCL Bluefish | Donepezil hydrochloride bluefish | Donepezil krka | Donesyn | Dozept</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Aricept | Asenta | Memorit</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Alzepil | Alzidoc | Alzil | Alzymer | Aricep | Arizex | Cognidep | Demenza | Donasure | Donaz | Donecept | Donep | Donetaz | Donibiz | Dope | Dopezil | Dorent | Lapezil | Nozil | Remenda</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Aricept | Destezil | Donepezil | Donepezil accord | Donepezil actavis | Donepezil almus | Donepezil aurobindo | Donepezil bluefish | Donepezil doc | Donepezil Eg | Donepezil germed | Donepezil mylan | Donepezil pensa | Donepezil ranbaxy | Donepezil Sandoz | Donepezil tecnigen | Donepezil teva italia | Donepezil zentiva | Lizidra | Memac | Yasnal | Yasnoro</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Alzancer | Aricept | Demenza | Donagen | Donazet | Donex | Doxera</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Aricept | Donepezil Hcl Amel | Donepezil hydrochloride kunihiro | Donepezil hydrochloride od kunihiro | Donepezil hydrochloride Towa</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Alzer | Aricept | Donecept | Torpezil</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">A Pezil fd | A-Pezil | Adone | Adope | Adozil | Ahngook donepezil | Alcept | Alchphil | Aldigm | Aldigm od | Aldocept | Alicete | Alicezil | Alite | Allopezil | Alpezil | Altsupezil | Altsupezil od | Alzcare | Alzcept | Alzmer | Anepezil | Aricept | Aricept Evess | Aridone | Arigen | Aripe | Aripezil | Arison | Arist | Arite | Arizet | Arocet | Artpezil | Aukocept | Bearcept | Bearcept odt | Brencept | Ceptpezil | Citpezil | Ctpezil | Demendone | Demenpezil | Demenpezil odt | Dimancare | Dimendone | Dimenpezil | Dimensept | Dimensol | Domentac | Donacept | Done cool | Doneable | Donecept | Donecept odt | Donecet | Donecia | Donecigi | Donedid | Donef | Doneforce | Donefujil | Donegreen | Doneil | Donel | Donemax | Donemin | Doneone | Donepa | Donepect | Donepem | Donepen | Donepet | Donepez | Donepezil | Donepezil hcl daewon | Donepezil hcl odt | Donepezil Jw | Donepezil one | Donepil | Donepin | Doneptin | Doneran | Donerin | Donet | Donete | Donetin | Donezen | Donezil | Donezin | Donpezil | Dope | Doperin | Dopezil | Dopinel | Doricept | Easypezil | Enpicept | Gcp donepezil | Genupharma donepezil hcl | Hanlim Donepezil | Hanwha donepezil | Hicept | Highsilverdone | Hipezil | Hipezil od | Hydone | Icept | Inist donepezil | J cept | J done | J pezil | Jw donepezil | Keicept | Mahapezil | Miracet | Nelson donepezil | Neocept | Neopezil | Neurocare | Neurocept | Neurodone | Neuropezil | Neutoin | Neutoin odf | Newcept | Newdonpizil | Onept | Penedo | Pharmdone | Remecept | S pezil | Samoh donepezil | Samsung donepezil | Silvercept | Silvercept od | Tdcept | Teva donepezil odt | Union donepezil | Unipezil | Varopezil | Vastia | Vastia od | WI Donepezil | Withupezil | Y cept</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Aricept</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Alzepil | Aricept | Aripezil | Donazet | Donecept | Donepezil Arrow | Donepezil biogaran | Dopezil</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Alertan | Alzepil | Aricept | Divare | Donepezil | Donepezil accord | Donepezil Orion | Dopomnil | Yasnal</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Aricept | Donepezil Eg | Donepezil hcl ratiopharm | Donepezil Sandoz</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Alzepil | Aricept | Donepezil accord | Donepezil actavis | Donepezil bluefish | Donepezil elpen | Donepezil puren | Donesyn | Yasnal</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Actacept | Aricept | Desenil | Donepezil zenith | Donzep | Dozicept | Dozyl</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Braix | Demalz | Donepezilo | Dozimev | Dubliet | Eranz | Jafizadane | Pegden | Pezzil | Sundonnez | Zydone</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Alzer | Aricept | Demealran | Donepezil/genepharm | Donezil | Tonizep | Torpezil</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Navazil</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Aricept | Donepezil | Donepezil accord | Donepezil aspen | Donepezil krka | Donepezil Orifarm | Donepezil Sandoz</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Aricept | Donepezil | Donezil</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Alisep | Carencil | Carencil odt | Diovol | Donecil | Donnez | Dozil | Eranz | Evocaz cd | Nicorvas</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Alnepezil | Alzancer | Aricept | Aricept Evess | Arizil | Done | Donezel | Dopezil | Servonex | Torpezil | Zypezil</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Azenil | Donecept | Donep | Donzil | Dopez | Dopzil | Dozido | Dozido d | Nepezil | Nepzil | Nimcept | Vastia | Vorizol | Zildon</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Alzdone | Alzepezil | Apo doperil | Aricept | Cogiton | Cognezil | Donecept | Donectil | Donemed | Donepesan | Donepex | Donepezil bluefish | Donepezil generics | Donepezil hydrochloride accord | Donepezil polfarmex | Doneprion | Donestad | Donesyn | Memocept | Memorion | Mensapex | Pamigen | Pezilgen | Ricordo | Symepezil | Yasnal</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Adlarity | Aricept | Donepezil | Donepezil HCL</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Alizil | Alkimus | Aricept | Dizil | Dizil odis | Donepezilo Accord | Donepezilo actavis | Donepezilo alter | Donepezilo aurobindo | Donepezilo azevedos | Donepezilo bluefish | Donepezilo bluepharma | Donepezilo ciclum | Donepezilo cinfa | Donepezilo Farmoz | Donepezilo Fixime | Donepezilo genedec | Donepezilo goldfarma | Donepezilo krka | Donepezilo medirex | Donepezilo mepha | Donepezilo Mylan | Donepezilo pharmakern | Donepezilo Ranbaxy | Donepezilo Ratiopharm | Donepezilo Sandoz | Donepezilo stada | Donepezilo teva | Donepezilo tolife | Donepezilo wynn | Donepezilo zentiva | Sofatin</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Butiral | Donecep | Doneclar | Donepecilo bauel top | Donepecilo libra | Donepecilo richmond | Donepezil hidrocloruro imedic | Donepezilo heisecke | Dopec | Dopecil | Evocaz cd | Vencel | Vencel odt</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Aricept</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Alzepil | Aricept | Aricept Evess | Cogiton | Cognezil | Darizol | Davia | Donecept | Donectil | Donepezil bluefish | Donepezil stada hemofarm | Donepezil teva | Donepezil torrent | Dospelin | Tuadin | Xalinat | Yasnal | Zildon</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Alzepil | Aricept | Dementis | Yasnal</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Dement | Dementile | Donecept | Pms donepezil</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Aricept | Azepezil | Donepezil accord | Donepezil actavis | Donepezil aspen | Donepezil aurobindo | Donepezil bluefish | Donepezil Ebb | Donepezil jubilant | Donepezil krka | Donepezil mylan | Donepezil Orifarm | Donepezil Orion | Donepezil Sandoz | Donepezil Stada | Donepezil teva</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Aricept</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Aricept | Donepezil actavis | Donepezil mylan | Donepezil Pliva | Donepezilijev klorid | Donezepil accord | Yasnal</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Adonep | Altzer | Aricept | Calofra | Cognezil | Donepezil +pharma | Donepezil accord | Donepezil bluefish | Donepezil mylan | Donepezil Orion | Donepezil teva | Donesyn | Landex | Medozil | Napezacta | Promemore | Yasnal | Yasnal Q</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Alzime | Aricept | Aricept Evess | Ceptia | Donept | Dopezil | Dozemo | Tonizep | Tonizep fdt</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Alzhecept | Arizil | Dopezil | Norocept</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Alzamed | Alzancer | Alzil | Aricept | Aricept Evess | Arypez | Dement | Dezira | Doenza | Dozyl | Dozyl easy | Memkar | Memoboost | Neurem | Zhedon</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Apo donepezil | Arcdone | Arezil | Aricept | Donepezil | Epalon | Nepes | Nomi Nox | Remecin | Rewise</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Almer | Alzepil | Donerum | Servonex</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Alzer</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Darial | Donep | Endoclar | Eranz | Maoxel | Oldinot | Piridon | Renacilo | Valpex</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Dazolin | Donaspen | Dozher | Eranz | Greit</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Rizax</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Aricept | Ariknow | Arimentia | Arimer | Curlovon | Donecept | Donepezil unicorn | Jubezil | Macleods donepezil | Nepizel | Zepanalz</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Torpezil</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-Adlarity.1">
<a name="Adlarity.1"></a>Adlarity (donepezil) [prescribing information]. Grand Rapids, MI: Corium Inc; March 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aricept.1">
<a name="Aricept.1"></a>Aricept (donepezil) tablets [prescribing information]. Nutley, NJ: Eisai Inc; November 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aricept.2">
<a name="Aricept.2"></a>Aricept (donepezil) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada Inc; December 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aricept.3">
<a name="Aricept.3"></a>Aricept tablets and orally disintegrating tablets (donepezil) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc; December 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10084551">
<a name="10084551"></a>Babic T, Zurak N. Convulsions induced by donepezil. <i>J Neurol Neurosurg Psychiatry</i>. 1999;66(3):410. doi:10.1136/jnnp.66.3.410<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/donepezil-drug-information/abstract-text/10084551/pubmed" id="10084551" target="_blank">10084551</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22249402">
<a name="22249402"></a>Bidzan L, Bidzan M. Withdrawal syndrome after donepezil cessation in a patient with dementia. <i>Neurol Sci</i>. 2012;33(6):1459-1461. doi:10.1007/s10072-012-0938-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/donepezil-drug-information/abstract-text/22249402/pubmed" id="22249402" target="_blank">22249402</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29923184">
<a name="29923184"></a>Birks JS, Harvey RJ. Donepezil for dementia due to Alzheimer's disease. <i>Cochrane Database Syst Rev</i>. 2018;6(6):CD001190. doi:10.1002/14651858.CD001190.pub3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/donepezil-drug-information/abstract-text/29923184/pubmed" id="29923184" target="_blank">29923184</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16696580">
<a name="16696580"></a>Bordier P, Garrigue S, Lanusse S, et al. Cardiovascular effects and risk of syncope related to donepezil in patients with Alzheimer's disease. <i>CNS Drugs</i>. 2006;20(5):411-417. doi:10.2165/00023210-200620050-00005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/donepezil-drug-information/abstract-text/16696580/pubmed" id="16696580" target="_blank">16696580</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10325453">
<a name="10325453"></a>Burns A, Rossor M, Hecker J, et al. The effects of donepezil in Alzheimer's disease - results from a multinational trial. <i>Dement Geriatr Cogn Disord</i>. 1999;10(3):237‐244. doi:10.1159/000017126<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/donepezil-drug-information/abstract-text/10325453/pubmed" id="10325453" target="_blank">10325453</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26918649">
<a name="26918649"></a>Chen YD, Zhang J, Wang Y, Yuan JL, Hu WL. Efficacy of cholinesterase inhibitors in vascular dementia: an updated meta-analysis. <i>Eur Neurol</i>. 2016;75(3-4):132-141. doi:10.1159/000444253<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/donepezil-drug-information/abstract-text/26918649/pubmed" id="26918649" target="_blank">26918649</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19447360">
<a name="19447360"></a>Daiello LA, Ott BR, Lapane KL, Reinert SE, Machan JT, Dore DD. Effect of discontinuing cholinesterase inhibitor therapy on behavioral and mood symptoms in nursing home patients with dementia. <i>Am J Geriatr Pharmacother</i>. 2009;7(2):74-83. doi:10.1016/j.amjopharm.2009.04.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/donepezil-drug-information/abstract-text/19447360/pubmed" id="19447360" target="_blank">19447360</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19186568">
<a name="19186568"></a>Dierckx RI, Vandewoude MF. Donepezil-related toxic hepatitis. <i>Acta Clin Belg</i>. 2008;63(5):339‐342. doi:10.1179/acb.2008.066<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/donepezil-drug-information/abstract-text/19186568/pubmed" id="19186568" target="_blank">19186568</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AvKARE.1">
<a name="AvKARE.1"></a>Donepezil hydrochloride extended release tablets [prescribing information]. Pulaski, TN: AvKARE Inc; March 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Torrent.1">
<a name="Torrent.1"></a>Donepezil [prescribing information]. Basking Ridge, NJ: Torrent Pharma Inc; January 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22915447">
<a name="22915447"></a>Dubois B, Tolosa E, Katzenschlager R, et al. Donepezil in Parkinson's disease dementia: a randomized, double-blind efficacy and safety study. <i>Mov Disord</i>. 2012;27(10):1230-1238. doi:10.1002/mds.25098<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/donepezil-drug-information/abstract-text/22915447/pubmed" id="22915447" target="_blank">22915447</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20678673">
<a name="20678673"></a>Farlow MR, Salloway S, Tariot PN, et al. Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: a 24-week, randomized, double-blind study. <i>Clin Ther</i>. 2010;32(7):1234‐1251. doi:10.1016/j.clinthera.2010.06.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/donepezil-drug-information/abstract-text/20678673/pubmed" id="20678673" target="_blank">20678673</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31527187">
<a name="31527187"></a>Fleet JL, McArthur E, Patel A, Weir MA, Montero-Odasso M, Garg AX. Risk of rhabdomyolysis with donepezil compared with rivastigmine or galantamine: a population-based cohort study. <i>CMAJ</i>. 2019;191(37):E1018‐E1024. doi:10.1503/cmaj.190337<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/donepezil-drug-information/abstract-text/31527187/pubmed" id="31527187" target="_blank">31527187</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31534872">
<a name="31534872"></a>Greiman TL, Dear BN, Wilkening GL. Adverse outcomes of abrupt switch and discontinuation of acetylcholinesterase inhibitors in dementia with Lewy bodies: Case report and literature review. <i>Ment Health Clin</i>. 2019;9(5):309-314. doi:10.9740/mhc.2019.09.309<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/donepezil-drug-information/abstract-text/31534872/pubmed" id="31534872" target="_blank">31534872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18686744">
<a name="18686744"></a>Hansen RA, Gartlehner G, Webb AP, Morgan LC, Moore CG, Jonas DE. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. <i>Clin Interv Aging</i>. 2008;3(2):211-225.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/donepezil-drug-information/abstract-text/18686744/pubmed" id="18686744" target="_blank">18686744</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hernandez.2016">
<a name="Hernandez.2016"></a>Hernandez I. Risk factors for cardiovascular events of antidementia drugs in Alzheimer’s disease patients. <i>Journal of Clinical Gerontology &amp; Geriatrics</i>. 2016;7(3):77-82.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26967222">
<a name="26967222"></a>Homma A, Atarashi H, Kubota N, Nakai K, Takase T. Efficacy and safety of sustained release donepezil high dose versus immediate release donepezil standard dose in Japanese patients with severe Alzheimer's disease: a randomized, double-blind trial. <i>J Alzheimers Dis</i>. 2016;52(1):345‐357. doi:10.3233/JAD-151149<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/donepezil-drug-information/abstract-text/26967222/pubmed" id="26967222" target="_blank">26967222</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11044775">
<a name="11044775"></a>Homma A, Takeda M, Imai Y, et al. Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease. A 24-week, multicenter, double-blind, placebo-controlled study in Japan. E2020 Study Group. <i>Dement Geriatr Cogn Disord</i>. 2000;11(6):299‐313. doi:10.1159/000017259<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/donepezil-drug-information/abstract-text/11044775/pubmed" id="11044775" target="_blank">11044775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22397651">
<a name="22397651"></a>Howard R, McShane R, Lindesay J, et al. Donepezil and memantine for moderate-to-severe Alzheimer's disease. <i>N Engl J Med</i>. 2012;366(10):893‐903. doi:10.1056/NEJMoa1106668<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/donepezil-drug-information/abstract-text/22397651/pubmed" id="22397651" target="_blank">22397651</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26515660">
<a name="26515660"></a>Howard R, McShane R, Lindesay J, et al. Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analyses. <i>Lancet Neurol</i>. 2015;14(12):1171‐1181. doi:10.1016/S1474-4422(15)00258-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/donepezil-drug-information/abstract-text/26515660/pubmed" id="26515660" target="_blank">26515660</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24777654">
<a name="24777654"></a>Howes LG. Cardiovascular effects of drugs used to treat Alzheimer's disease. <i>Drug Saf</i>. 2014;37(6):391-395.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/donepezil-drug-information/abstract-text/24777654/pubmed" id="24777654" target="_blank">24777654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16553494">
<a name="16553494"></a>Hughes A, Musher J, Thomas SK, Beusterien KM, Strunk B, Arcona S. Gastrointestinal adverse events in a general population sample of nursing home residents taking cholinesterase inhibitors. <i>Consult Pharm</i>. 2004;19(8):713-720. doi:10.4140/tcp.n.2004.713<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/donepezil-drug-information/abstract-text/16553494/pubmed" id="16553494" target="_blank">16553494</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25484499">
<a name="25484499"></a>Hundae A, Afzal A, Assar MD, Schussler JM. Syncope secondary to second-degree atrioventricular block with donepezil use. <i>Proc (Bayl Univ Med Cent)</i>. 2014;27(4):325-326. doi:10.1080/08998280.2014.11929146<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/donepezil-drug-information/abstract-text/25484499/pubmed" id="25484499" target="_blank">25484499</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23949147">
<a name="23949147"></a>Ikeda M, Mori E, Kosaka K, et al; Donepezil-DLB Study Investigators. Long-term safety and efficacy of donepezil in patients with dementia with Lewy bodies: results from a 52-week, open-label, multicenter extension study. <i>Dement Geriatr Cogn Disord</i>. 2013;36(3-4):229-241. doi:10.1159/000351672<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/donepezil-drug-information/abstract-text/23949147/pubmed" id="23949147" target="_blank">23949147</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25713599">
<a name="25713599"></a>Ikeda M, Mori E, Matsuo K, Nakagawa M, Kosaka K. Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled, confirmatory phase III trial. <i>Alzheimers Res Ther</i>. 2015;7(1):4. doi:10.1186/s13195-014-0083-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/donepezil-drug-information/abstract-text/25713599/pubmed" id="25713599" target="_blank">25713599</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29851022">
<a name="29851022"></a>Isik AT, Soysal P, Stubbs B, et al. Cardiovascular outcomes of cholinesterase inhibitors in individuals with dementia: a meta-analysis and systematic review. <i>J Am Geriatr Soc</i>. 2018;66(9):1805-1811. doi:10.1111/jgs.15415<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/donepezil-drug-information/abstract-text/29851022/pubmed" id="29851022" target="_blank">29851022</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18978490">
<a name="18978490"></a>Kim YW, Kim DY, Shin JC, Park CI, Lee JD. The changes of cortical metabolism associated with the clinical response to donepezil therapy in traumatic brain injury. <i>Clin Neuropharmacol.</i> 2009;32(2):63-68.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/donepezil-drug-information/abstract-text/18978490/pubmed" id="18978490" target="_blank">18978490</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20036167">
<a name="20036167"></a>Kumlien E, Lundberg PO. Seizure risk associated with neuroactive drugs: data from the WHO adverse drug reactions database. <i>Seizure</i>. 2010;19(2):69‐73. doi:10.1016/j.seizure.2009.11.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/donepezil-drug-information/abstract-text/20036167/pubmed" id="20036167" target="_blank">20036167</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17855324">
<a name="17855324"></a>Leitch A, McGinness P, Wallbridge D. Calculate the QT interval in patients taking drugs for dementia. <i>BMJ</i>. 2007;335(7619):557. doi:10.1136/bmj.39020.710602.47<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/donepezil-drug-information/abstract-text/17855324/pubmed" id="17855324" target="_blank">17855324</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24589768">
<a name="24589768"></a>Leung JG. Donepezil-induced mania. <i>Consult Pharm</i>. 2014;29(3):191‐195. doi:10.4140/TCP.n.2014.191<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/donepezil-drug-information/abstract-text/24589768/pubmed" id="24589768" target="_blank">24589768</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29736156">
<a name="29736156"></a>Lim EY, Yang DW, Kim JS, Cho AH. Safety and efficacy of anti-dementia agents in the extremely elderly patients with dementia. <i>J Korean Med Sci</i>. 2018;33(19):e133. doi:10.3346/jkms.2018.33.e133<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/donepezil-drug-information/abstract-text/29736156/pubmed" id="29736156" target="_blank">29736156</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19893314">
<a name="19893314"></a>Lockhart IA, Mitchell SA, Kelly S. Safety and tolerability of donepezil, rivastigmine and galantamine for patients with Alzheimer's disease: systematic review of the 'real-world' evidence. <i>Dement Geriatr Cogn Disord</i>. 2009;28(5):389-403. doi:10.1159/000255578<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/donepezil-drug-information/abstract-text/19893314/pubmed" id="19893314" target="_blank">19893314</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14731314">
<a name="14731314"></a>Matsumoto T, Kawanishi C, Isojima D, et al. Neuroleptic malignant syndrome induced by donepezil. <i>Int J Neuropsychopharmacol</i>. 2004;7(1):101-103. doi:10.1017/S1461145703003857<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/donepezil-drug-information/abstract-text/14731314/pubmed" id="14731314" target="_blank">14731314</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22829268">
<a name="22829268"></a>Mori E, Ikeda M, Kosaka K; Donepezil-DLB Study Investigators. Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial. <i>Ann Neurol</i>. 2012;72(1):41-52. doi:10.1002/ana.23557<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/donepezil-drug-information/abstract-text/22829268/pubmed" id="22829268" target="_blank">22829268</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15496219">
<a name="15496219"></a>Nagy CF, Kumar D, Cullen EI, et al. Steady-state pharmacokinetics and safety of donepezil HCl in subjects with moderately impaired renal function. <i>Br J</i>
<i>Clin Pharmacol</i>. 2004;58(suppl 1):S18-S24. doi:10.1111/j.1365-2125.2004.01803.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/donepezil-drug-information/abstract-text/15496219/pubmed" id="15496219" target="_blank">15496219</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.2018">
<a name="NICE.2018"></a>National Institute for Health and Care Excellence (NICE). Dementia: assessment, management and support for people living with dementia and their carers. NICE guideline 97. https://www.nice.org.uk/guidance/ng97/evidence/full-guideline-pdf-4852695709. Published June 2018. Accessed March 31, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.1">
<a name="NICE.1"></a>National Institute for Health and Care Excellence (NICE). Parkinson’s disease in adults. NICE guideline 71. https://www.nice.org.uk/guidance/ng71/resources/parkinsons-disease-in-adults-pdf-1837629189061. Published July 2017. Accessed March 30, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31470743">
<a name="31470743"></a>Niinomi I, Hosohata K, Oyama S, Inada A, Wakabayashi T, Iwanaga K. Pharmacovigilance assessment of drug-induced acute pancreatitis using a spontaneous reporting database. <i>Int J Toxicol</i>. 2019;38(6):487‐492. doi:10.1177/1091581819870717<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/donepezil-drug-information/abstract-text/31470743/pubmed" id="31470743" target="_blank">31470743</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28103749">
<a name="28103749"></a>O'Brien JT, Holmes C, Jones M, et al. Clinical practice with anti-dementia drugs: a revised (third) consensus statement from the British Association for Psychopharmacology. <i>J Psychopharmacol</i>. 2017;31(2):147-168. doi:10.1177/0269881116680924<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/donepezil-drug-information/abstract-text/28103749/pubmed" id="28103749" target="_blank">28103749</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21648211">
<a name="21648211"></a>Prescrire Int. Bradycardia due to cholinesterase inhibitors: identify adverse effects and take them into account. <i>Prescrire Int</i>. 2011;20(115):95.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/donepezil-drug-information/abstract-text/21648211/pubmed" id="21648211" target="_blank">21648211</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18340692">
<a name="18340692"></a>Rabins PV, Blacker D, Rovner BW, et al; APA Work Group on Alzheimer's Disease and Other Dementias. American Psychiatric Association practice guideline for the treatment of patients with Alzheimer's disease and other dementias. Second edition. <i>Am J Psychiatry</i>. 2007;164(12)(suppl):5-56.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/donepezil-drug-information/abstract-text/18340692/pubmed" id="18340692" target="_blank">18340692</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31997970">
<a name="31997970"></a>Rabins PV, Rovner BW, Rummans T, Schneider LS, Tariot PN. Guideline Watch (October 2014): practice guideline for the treatment of patients with Alzheimer's disease and other dementias. <i>Focus (Am Psychiatr Publ)</i>. 2017;15(1):110‐128. doi:10.1176/appi.focus.15106<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/donepezil-drug-information/abstract-text/31997970/pubmed" id="31997970" target="_blank">31997970</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30771226">
<a name="30771226"></a>Reeve E, Farrell B, Thompson W, et al. Deprescribing cholinesterase inhibitors and memantine in dementia: guideline summary. <i>Med J Aust</i>. 2019;210(4):174-179. doi:10.5694/mja2.50015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/donepezil-drug-information/abstract-text/30771226/pubmed" id="30771226" target="_blank">30771226</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14999113">
<a name="14999113"></a>Roden DM. Drug-induced prolongation of the QT interval. <i>N Engl J Med</i>. 2004;350(10):1013-1022. doi:10.1056/NEJMra032426<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/donepezil-drug-information/abstract-text/14999113/pubmed" id="14999113" target="_blank">14999113</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24864216">
<a name="24864216"></a>Sahin OZ, Ayaz T, Yuce S, et al. A rare case of acute renal failure secondary to rhabdomyolysis probably induced by donepezil [published online April 27, 2014]. <i>Case Rep Nephrol</i>. 2014;2014:214359. doi:10.1155/2014/214359<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/donepezil-drug-information/abstract-text/24864216/pubmed" id="24864216" target="_blank">24864216</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Shareef.2017">
<a name="Shareef.2017"></a>Shareef J, Joseph J, Adithi K. A single case report on hyponatremia seizure induced by acetylcholinesterase inhibitors. <i>International Journal of Pharmacy and Pharmaceutical Sciences</i>. 2017;9(7):165-166. doi:10.22159/ijpps.2017v9i7.19057</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26234945">
<a name="26234945"></a>Sheffrin M, Miao Y, Boscardin WJ, Steinman MA. Weight loss associated with cholinesterase inhibitors in individuals with dementia in a national healthcare system. <i>J Am Geriatr Soc</i>. 2015;63(8):1512-1518. doi:10.1111/jgs.13511<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/donepezil-drug-information/abstract-text/26234945/pubmed" id="26234945" target="_blank">26234945</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12673601">
<a name="12673601"></a>Singh S, Dudley C. Discontinuation syndrome following donepezil cessation. <i>Int J Geriatr Psychiatry</i>. 2003;18(4):282-284. doi:10.1002/gps.811<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/donepezil-drug-information/abstract-text/12673601/pubmed" id="12673601" target="_blank">12673601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27261502">
<a name="27261502"></a>Soysal P, Isik AT, Stubbs B, et al. Acetylcholinesterase inhibitors are associated with weight loss in older people with dementia: a systematic review and meta-analysis. <i>J Neurol Neurosurg Psychiatry</i>. 2016;87(12):1368-1374. doi:10.1136/jnnp-2016-313660<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/donepezil-drug-information/abstract-text/27261502/pubmed" id="27261502" target="_blank">27261502</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16858101">
<a name="16858101"></a>Suleyman T, Tevfik P, Abdulkadir G, Ozlem S. Complete atrioventricular block and ventricular tachyarrhythmia associated with donepezil. <i>Emerg Med J</i>. 2006;23(8):641-642. doi:10.1136/emj.2006.036251<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/donepezil-drug-information/abstract-text/16858101/pubmed" id="16858101" target="_blank">16858101</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12053074">
<a name="12053074"></a>Suwata J, Kamata K, Nishijima T, Yoshikawa T, Sano M. New acetylcholinesterase inhibitor (donepezil) treatment for Alzheimer's disease in a chronic dialysis patient. <i>Nephron</i>. 2002;91(2):330-332. doi:10.1159/000058413<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/donepezil-drug-information/abstract-text/12053074/pubmed" id="12053074" target="_blank">12053074</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19602789">
<a name="19602789"></a>Tanaka A, Koga S, Hiramatsu Y. Donepezil-induced adverse side effects of cardiac rhythm: 2 cases report of atrioventricular block and torsade de pointes. <i>Intern Med</i>. 2009;48(14):1219-1223. doi:10.2169/internalmedicine.48.2181<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/donepezil-drug-information/abstract-text/19602789/pubmed" id="19602789" target="_blank">19602789</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23716032">
<a name="23716032"></a>Tisdale JE, Jaynes HA, Kingery JR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. <i>Circ Cardiovasc Qual Outcomes</i>. 2013;6(4):479-487. doi:10.1161/CIRCOUTCOMES.113.000152 Erratum in: <i>Circ Cardiovasc Qual Outcomes</i>. 2013;6(6):e57.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/donepezil-drug-information/abstract-text/23716032/pubmed" id="23716032" target="_blank">23716032</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32929996">
<a name="32929996"></a>Tisdale JE, Chung MK, Campbell KB, et al; American Heart Association Clinical Pharmacology Committee of the Council on Clinical Cardiology and Council on Cardiovascular and Stroke Nursing. Drug-induced arrhythmias: A scientific statement from the American Heart Association. <i>Circulation</i>. 2020;142(15):e214-e233. doi:10.1161/CIR.0000000000000905<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/donepezil-drug-information/abstract-text/32929996/pubmed" id="32929996" target="_blank">32929996</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9839768">
<a name="9839768"></a>Tiseo PJ, Foley K, Friedhoff LT. An evaluation of the pharmacokinetics of donepezil HCl in patients with moderately to severely impaired renal function. <i>Br J Clin Pharmaco</i>l. 1998;46(suppl 1):S56-S60. doi:10.1046/j.1365-2125.1998.0460s1056.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/donepezil-drug-information/abstract-text/9839768/pubmed" id="9839768" target="_blank">9839768</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11129758">
<a name="11129758"></a>Verrico MM, Nace DA, Towers AL. Fulminant chemical hepatitis possibly associated with donepezil and sertraline therapy. <i>J Am Geriatr Soc</i>. 2000;48(12):1659‐1663. doi:10.1111/j.1532-5415.2000.tb03879<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/donepezil-drug-information/abstract-text/11129758/pubmed" id="11129758" target="_blank">11129758</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24828899">
<a name="24828899"></a>Wang HF, Yu JT, Tang SW, et al. Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis. <i>J Neurol Neurosurg Psychiatry</i>. 2015;86(2):135‐143. doi:10.1136/jnnp-2014-307659<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/donepezil-drug-information/abstract-text/24828899/pubmed" id="24828899" target="_blank">24828899</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18212788">
<a name="18212788"></a>Warwick TC, Moningi V, Jami P, et al. Neuroleptic malignant syndrome variant in a patient receiving donepezil and olanzapine.<i> Nat Clin Pract Neurol</i>. 2008;4(3):170-174. doi:10.1038/ncpneuro0728<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/donepezil-drug-information/abstract-text/18212788/pubmed" id="18212788" target="_blank">18212788</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31616673">
<a name="31616673"></a>Yiannopoulou KG, Anastasiou AI, Kyrozis A, Anastasiou IP. Donepezil treatment for Alzheimer's disease in chronic dialysis patients. <i>Case Rep Nephrol</i>
<i>Dial</i>. 2019;9(3):126-136. doi:10.1159/000502682<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/donepezil-drug-information/abstract-text/31616673/pubmed" id="31616673" target="_blank">31616673</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9383 Version 530.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
